About: http://webisa.webdatacommons.org/436215971

Property	Value
http://www.w3.org/1999/02/22-rdf-syntax-ns#type	http://www.w3.org/ns/prov#Entity
http://www.w3.org/ns/prov#value	The gross proceeds to MAP Pharmaceuticals from this offering are expected to be approximately $52 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by MAP Pharmaceuticals.
http://www.w3.org/ns/prov#wasQuotedFrom	biospace.com